The US FTC concludes that a pharma company entered into an illegal pay-for-delay agreement (Endo / Impax)

On March 28, 2019, the Federal Trade Commission (the “Commission”) issued a landmark opinion in the agency’s case against Impax Laboratories Inc. regarding its patent settlement with Endo Pharmaceuticals Inc., marking the first time that the Commission has weighed in on the proper application of the Supreme Court’s Actavis antitrust evaluation framework for “reverse payment” settlements. [1] Highlighting multiple Actavis “red flags,” the Commission concluded that the settlement raised the precise antitrust concerns that led the Supreme Court to subject these types of agreements to antitrust scrutiny, which provided guidance to lower courts confronting these challenging and nuanced issues in future cases. Factual Background Endo received FDA approval and launched Opana ER in 2006. In 2007,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Katie R. Beran, Melinda R. Coolidge, The US FTC concludes that a pharma company entered into an illegal pay-for-delay agreement (Endo / Impax), 28 March 2019, e-Competitions Intellectual property, Art. N° 96409

Visites 52

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues